Funding for this research was provided by:
Instituto de Salud Carlos III (RD16/0015/0011, FIS/PI17/00254)
Ministerio de Economía, Industria y Competitividad, Gobierno de España (SAF 2016-80363-C2-1-R)
FP7 Ideas: European Research Council (PCIN-2015-191-C02-01)
Received: 19 March 2020
Accepted: 11 May 2020
First Online: 20 May 2020
Ethics approval and consent to participate
: The study was approved by the local ethics committee (Hospital del Mar Research Institute, IMIM, ethic approval number: 2016/6607/I). Patients gave written informed consent to enter the study and provide peripheral blood samples.
: Not applicable.
: A. Zabalza has received travel funding from Biogen Idec, Novartis, and Genzyme. A. Moreira has received travel funding from Teva, Biogen Idec, Novartis, Almirall, Bayer, and Genzyme, and personal fees for lectures from Genzyme. E. Munteis has received personal fees for consulting services and lectures from Merck-Serono, Biogen Idec, Teva, Genzyme, Novartis, Bayer, and Almirall. JE. Martínez-Rodríguez has participated as principal investigator in pharmaceutical company-sponsored clinical trials including Novartis, Roche, Merck-Serono, Actelion, and Celgene, and personal fees for consulting services and lectures from Novartis, Biogen Idec, and Merck-Serono. A Vera, E. Alari-Pahissa, J. Yélamos, M. Llop, and M. López-Botet declare that they have no competing interests.